6:33 PM
 | 
Oct 15, 2012
 |  BC Extra  |  Clinical News

Lilly's ramucirumab meets OS endpoint in gastric cancer

Eli Lilly and Co. (NYSE:LLY) said ramucirumab met the primary endpoint in the Phase III REGARD trial to treat metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum or fluoropyrimidine-containing combination therapy. Ramucirumab given...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >